This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

image of severe asthma in lung section

Available via

WEBINAR

Severe Asthma: Novel Concepts & Therapeutics

Friday, April 26, 2019, 8:30 AM - 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The New York Academy of Sciences

The Biochemical Pharmacology Discussion Group

 

Asthma is a chronic, heterogeneous inflammatory disease of the airways, affecting approximately 300 million people worldwide. Severe asthma is defined as an uncontrolled or only partially controlled form of asthma despite intensive treatment. It affects 5-10% of the adult asthma population and is associated with increased morbidity, mortality, and consumption of health care resources. Limited knowledge of the disease mechanisms is the greatest obstacle to the development of novel treatments. This symposium will focus on novel insights into the pathophysiology of severe asthma as well as on offering perspectives on potential new therapeutic opportunities.

Photo courtesy of Dylan Birchard, Regeneron

Call for Abstracts

Abstract submissions are invited for a poster session. Top poster abstracts will be selected for short talks. For complete submission instructions, please visit our online portal. The deadline for abstract submission is February 26, 2019.

Registration

Member
By 03/15/2019
$90
After 03/15/2019
$130
Nonmember Academia, Faculty, etc.
By 03/15/2019
$180
After 03/15/2019
$260
Nonmember Corporate, Other
By 03/15/2019
$250
After 03/15/2019
$350
Nonmember Not for Profit
By 03/15/2019
$180
After 03/15/2019
$260
Nonmember Student, Undergrad, Grad, Fellow
By 03/15/2019
$100
After 03/15/2019
$145
Member Student, Post-Doc, Fellow
By 03/15/2019
$50
After 03/15/2019
$70
Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$0
Earlybird Registration:
26
days
left
Deadline:
9
days
left

Scientific Organizing Committee

David Artis, PhD,  Weill Cornell Medicine
David Artis, PhD,
Weill Cornell Medicine
Roland Kolbeck, PhD,  MedImmune
Roland Kolbeck, PhD,
MedImmune
Jamie Orengo, PhD,  Regeneron
Jamie Orengo, PhD,
Regeneron
Matthew Sleeman, PhD,  Regeneron
Matthew Sleeman, PhD,
Regeneron
Sonya Dougal, PhD,  The New York Academy of Sciences
Sonya Dougal, PhD,
The New York Academy of Sciences
Marie Samanovic-Golden, PhD,  The New York Academy of Sciences
Marie Samanovic-Golden, PhD,
The New York Academy of Sciences

Keynote Speakers

Bart N. Lambrecht, MD, PhD,  Ghent University
Bart N. Lambrecht, MD, PhD,
Ghent University
Sally Wenzel, MD
Sally Wenzel, MD

University of Pittsburgh

Speakers

David Artis, PhD,  Weill Cornell Medicine 
David Artis, PhD,
Weill Cornell Medicine
Kathleen Barnes, PhD
Kathleen Barnes, PhD

University of Colorado Denver

Alison Humbles, PhD, MedImmune
Alison Humbles, PhD,
MedImmune
Melanie Königshoff, MD, PhD, University of Colorado Denver
Melanie Königshoff, MD, PhD,
University of Colorado Denver
James Martin, MD,  McGill University
James Martin, MD,
McGill University
Kari Nadeau, MD, PhD,  Stanford University  School of Medicine
Kari Nadeau, MD, PhD,
Stanford University
School of Medicine
Jamie Orengo, PhD,  Regeneron
Jamie Orengo, PhD,
Regeneron
Xin Sun, PhD,  University of California  San Diego
Xin Sun, PhD,
University of California
San Diego

Program Support





Friday

April 26, 2019

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Speakers

Marie Samanovic-Golden, PhD
The New York Academy of Sciences
Matthew Sleeman, PhD
Regeneron
9:15 AM

Keynote Address: Molecular Phenotyping meets Molecular Targeting: Are We Closer to Asthma Endotypes?

Speaker

Sally Wenzel, MD
University of Pittsburgh Asthma Institute

For years asthma was considered one disease, defined by bronchodilator responsiveness and appropriate symptoms and often as an allergic childhood onset disease responsive to corticosteroids (CS). While this promoted widespread CS use, despite being effective in many, CSs were remarkably ineffective in others. Yet the reasons for this heterogeneity, particularly obvious in severe asthma, were unclear. Whole genome transcriptional analysis and targeted biologic therapies have greatly expanded our understanding of this heterogeneity. ‘Omics studies identified a Type-2 (T2) immuno-inflammatory signature in mild asthma which can persist despite high inhaled and systemic CS doses in severe asthma. Concurrent studies of targeted biologic therapies showed efficacy over that of CS and long acting beta agonists. Thus, molecular phenotypes of Type-2 Hi asthma were consistently recognized. However, even Type-2 Hi asthma is highly heterogeneous, with differing responses to T2 targeted therapies despite associated biomarker elevation. Some severe asthma may also go beyond T2 inflammation alone. Type-1 inflammation is increasingly recognized as playing a role in some, often in combination with T2 inflammation. A role for Type-17 inflammation is less clear. Additional metabolic abnormalities may also contribute to worsening refractory T2 (and non T2) inflammation. Thus, our understanding has allowed us to identify molecular phenotypes of asthma. Identifying an endotype requires linking a particular pathologic pathway as central to a clinical phenotype, through targeted approaches, which should improve the disease in every case. While we are getting close, further work remains to truly define an asthma “endotype”..

Session 1: New Insights in the Immunology of Severe Asthma

Session Chairperson
Matthew Sleeman, PhD, Regeneron
10:00 AM

The Role of Epithelial Cytokines and Innate Lymphoid Cells in Lung Inflammation and Repair

Speaker

David Artis, PhD
Weill Cornell Medicine
10:30 AM

Networking Coffee Break

11:00 AM

The Role of Eosinophils and Basophils in Asthma

Speaker

Alison Humbles, PhD
MedImmune
11:30 AM

Type 2 Cytokines and Their Impact on Smooth Muscle Cells and Bronchial Constriction in Asthma

Speaker

James Martin, MD
McGill University

Session 2: Data Blitz Talks — Short Talks Selected from Submitted Abstracts

Session Chairperson
Matthew Sleeman, PhD, Regeneron
12:00 PM

Selection from Submitted Abstracts

12:05 PM

Selection from Submitted Abstracts

12:10 PM

Networking Lunch and Poster Session

Session 3: Novel Concepts in the Pathophysiology of Asthma

Session Chairperson
Roland Kolbeck, PhD, MedImmune
1:10 PM

Severe Asthma in a Changing World

Speaker

Kari Nadeau, MD, PhD
Stanford University School of Medicine
1:40 PM

Pulmonary Neuroendocrine Cells, and Unexpected Player in Asthma

Speaker

Xin Sun, PhD
University of California San Diego
2:10 PM

The Genetics of Asthma

Speaker

Kathleen Barnes, PhD
University of Colorado School of Medicine
2:40 PM

Networking Coffee Break

3:10 PM

Keynote Address: Spontaneous Protein Crystallization in Asthma

Speaker

Bart N. Lambrecht, MD, PhD
Ghent University

Session 4: Emerging Therapeutics to Target Severe Asthma

Session Chairperson
David Artis, PhD, Weill Cornell Medicine
3:55 PM

Lung Regeneration and Repair

Speaker

Melanie Königshoff, MD, PhD
University of Colorado Denver
4:25 PM

Novel Therapeutics Targeting Type 2 Cytokines in Severe Asthma

Speaker

Jamie Orengo, PhD
Regeneron
4:55 PM

Closing Remarks and F1000 Poster Prize Presentation

Speaker

David Artis, PhD
Weill Cornell Medicine
5:00 PM

Networking Reception

6:00 PM

Adjourn